SSKI

Iodine Therapy

 
NOTE: Enteric-coated potassium iodide tablets have been associated with severe complications which have resulted in death and are not recommended for use.

All dosage forms: To minimize GI irritation, administer after meals or with milk.

Oral tablets: 
Potassium iodide tablets are used only for the treatment of radiation emergencies.

Saturated Solution of Potassium Iodide (SSKI) oral solution 1 gram/mL:
Administer using a calibrated measuring device (e.g., the provided dropper) to ensure accurate dosing.
Mix dose in 240 mL of water, fruit juice, or milk prior to administration.
To minimize gastric irritation, administer with food or milk.
SSKI solution is normally clear and colorless. A slightly darkened solution does not indicate loss of potency. If the solution turns brownish-yellow in color, it should be discarded. The saturated solutions may crystallize on exposure to cold temperatures; allowing to warm to room temperature with shaking may redissolve crystals.
 
Potassium Iodide oral solutions or syrups (65 mg/mL):
Administer using a calibrated measuring device (e.g., the provided dropper) to ensure accurate dosing.
When used for radiation emergencies: Administer once every day (every 24 hours) as directed by public officials. Do not administer more than 1 dose in 24 hours.
 
Extemporaneous compounding instructions for potassium iodide liquid mixture (8.125 mg/5 mL or 16.25 mg/5 mL):
Put either one 65 mg or one 130 mg potassium iodide tablet into a small bowl and grind it into a fine powder using the back of a metal teaspoon against the inside of the bowl. The powder should not have any large pieces.
Add 4 teaspoonfuls of water to the crushed powder in the bowl and mix until the potassium iodide powder is dissolved in the water.
Mix the potassium iodide water solution with 4 teaspoonfuls of low fat white or chocolate milk, orange juice, flat soda, raspberry syrup, or infant formula.
NOTE: If a 65 mg tablet was used, the concentration is 8.125 mg potassium iodide/5 mL. If a 130 mg tablet was used, the concentration is 16.25 mg potassium iodide/5 mL.
Storage: May be stored for up to 7 days in the refrigerator. Discard any unused portions.

GI bleeding / Delayed / Incidence not known
iodine toxicity / Delayed / Incidence not known
angioedema / Rapid / Incidence not known
serum sickness / Delayed / Incidence not known

sialadenitis / Delayed / Incidence not known
thyroid adenoma / Delayed / Incidence not known
goiter / Delayed / Incidence not known
hypothyroidism / Delayed / Incidence not known
dysphagia / Delayed / Incidence not known
lymphadenopathy / Delayed / Incidence not known
eosinophilia / Delayed / Incidence not known
wheezing / Rapid / Incidence not known

vomiting / Early / Incidence not known
nausea / Early / Incidence not known
diarrhea / Early / Incidence not known
acneiform rash / Delayed / Incidence not known
ocular irritation / Rapid / Incidence not known
blepharedema / Early / Incidence not known
sneezing / Early / Incidence not known
metallic taste / Early / Incidence not known
rhinitis / Early / Incidence not known
headache / Early / Incidence not known
arthralgia / Delayed / Incidence not known
fever / Early / Incidence not known

SSKI

Rx, OTC

Oral antithyroid agent containing roughly 76% iodine and 23% potassium by weight
Used as an adjunct to other antithyroid agents in the treatment of hyperthyroidism and thyrotoxicosis and preoperatively to induce thyroid involution
Certain formulations are approved only for thyroid protection against radioactive iodine (I-131) exposure during radiation emergencies

130 mg PO once daily, taken as soon as possible after exposure. The effectiveness of potassium iodide as a specific blocker of thyroid radioiodine uptake is well established, with the benefits of each dose lasting approximately 24 hours. Daily treatment should continue until public officials have determined it is safe to discontinue therapy. In general, daily dosing should continue until the risk of exposure has passed or until other adjunctive measures (e.g., evacuation, sheltering, and control of the food and milk supply) have been successfully implemented. The FDA emphasizes that the overall benefits of potassium iodide far exceed the risk of overdosing in this situation.

130 mg PO once, taken as soon as possible after exposure. Women who are pregnant or breast-feeding should consult with a healthcare provider before taking repeated doses. Particular attention should be paid to the dose and duration of treatment for women who are pregnant. The FDA has specifically recommended that pregnant women be given priority with regard to adjunctive measures like evacuation in order to obviate the need for repeat dosing with potassium iodide. The protective effects of a single dose lasts approximately 24 hours.

130 mg PO once daily, taken as soon as possible after exposure. The effectiveness of potassium iodide as a specific blocker of thyroid radioiodine uptake is well established, with the benefits of each dose lasting approximately 24 hours. Daily treatment should continue until public officials have determined it is safe to discontinue therapy. In general, daily dosing should continue until the risk of exposure has passed or until other adjunctive measures (e.g., evacuation, sheltering, and control of the food and milk supply) have been successfully implemented. The FDA emphasizes that the overall benefits of potassium iodide far exceed the risk of overdosing in this situation.

65 mg PO once daily, taken as soon as possible after exposure. The effectiveness of potassium iodide as a specific blocker of thyroid radioiodine uptake is well established, with the benefits of each dose lasting approximately 24 hours. Daily treatment should continue until public officials have determined it is safe to discontinue therapy. In general, daily dosing should continue until the risk of exposure has passed or until other adjunctive measures (e.g., evacuation, sheltering, and control of the food and milk supply) have been successfully implemented. The FDA emphasizes that the overall benefits of potassium iodide far exceed the risk of overdosing in this situation.

65 mg PO once daily, taken as soon as possible after exposure. The effectiveness of potassium iodide as a specific blocker of thyroid radioiodine uptake is well established, with the benefits of each dose lasting approximately 24 hours. Daily treatment should continue until public officials have determined it is safe to discontinue therapy. In general, daily dosing should continue until the risk of exposure has passed or until other adjunctive measures (e.g., evacuation, sheltering, and control of the food and milk supply) have been successfully implemented. The FDA emphasizes that the overall benefits of potassium iodide far exceed the risk of overdosing in this situation.

32.5 mg PO once daily, taken as soon as possible after exposure. The effectiveness of potassium iodide as a specific blocker of thyroid radioiodine uptake is well established, with the benefits of each dose lasting approximately 24 hours. Daily treatment should continue until public officials have determined it is safe to discontinue therapy. In general, daily dosing should continue until the risk of exposure has passed or until other adjunctive measures (e.g., evacuation, sheltering, and control of the food and milk supply) have been successfully implemented. The FDA emphasizes that the overall benefits of potassium iodide far exceed the risk of overdosing in this situation.

16.25 mg PO once, taken as soon as possible after exposure. Consult with a healthcare provider before administering repeated doses. The FDA has specifically recommended that newborns be given priority with regard to adjunctive measures (like evacuation) in order to obviate the need for repeat dosing with potassium iodide. The protective effects of a single dose lasts approximately 24 hours.

0.3 mL (300 mg) or 0.6 mL (600 mg) PO 3 to 4 times daily, diluted in a glassful of water, fruit juice, or milk. Use no longer than necessary to produce the desired effect. Although this recommendation is found in the manufacturer label, this drug has not been found by FDA to be safe and effective for this purpose has not been approved by the FDA's drug approval process. Due to the potential for adverse effects and lack of evidence of proven efficacy, guidelines do not recommend the use of iodinated products for the treatment of cough or expectoration.

250 mg PO every 6 hours. Do not start until 1 hour after antithyroid drugs.

50 to 250 mg PO every 8 hours. Do not start until 1 hour after antithyroid drugs.

50 to 100 mg PO every 8 hours for 10 days before thyroidectomy when it is not possible to render a person with Grave's disease euthyroid before thyroidectomy, thyroidectomy is urgent, or when the person is allergic to antithyroid drugs.

50 to 200 mg PO every 8 hours for 7 to 14 days before thyroidectomy when it is not possible to render a person with Grave's disease euthyroid before thyroidectomy, thyroidectomy is urgent, or when the person is allergic to antithyroid drugs.

5 drops PO 3 times daily, initially. Increase as tolerated to 40 to 50 drops PO 3 times daily for 2 to 4 weeks after all lesions have resolved, usually for a total of 3 to 6 months in patients who do not respond to itraconazole.[50784]

1 drop PO 3 times daily, initially. Increase as tolerated to 1 drop/kg/dose (Max: 40 to 50 drops/dose) PO 3 times daily, whichever is lower, for 2 to 4 weeks after all lesions have resolved, usually for a total of 3 to 6 months in patients who do not respond to itraconazole.[50784]

†Indicates off-label use

Specific information is not available; however, it appears no dosage adjustment is needed.

Dosage should be modified depending on clinical response and degree of renal impairment.

Acetaminophen; Ibuprofen: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and nonsteroidal anti-inflammatory drugs (NSAIDs) are used together. Concomitant use may increase the risk of hyperkalemia.
Aliskiren: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and aliskiren are used together. Concomitant use may increase the risk of hyperkalemia.
Aliskiren; Hydrochlorothiazide, HCTZ: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and aliskiren are used together. Concomitant use may increase the risk of hyperkalemia.
Amiloride: (Major) The use of potassium supplements in patients treated with amiloride is generally contraindicated. Concomitant use may increase the risk of hyperkalemia. If potassium supplementation is used, monitor serum potassium concentrations closely.
Amiloride; Hydrochlorothiazide, HCTZ: (Major) The use of potassium supplements in patients treated with amiloride is generally contraindicated. Concomitant use may increase the risk of hyperkalemia. If potassium supplementation is used, monitor serum potassium concentrations closely.
Amlodipine; Benazepril: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin-converting enzyme inhibitors (ACE inhibitors) are used together. Concomitant use may increase the risk of hyperkalemia.
Amlodipine; Celecoxib: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and nonsteroidal anti-inflammatory drugs (NSAIDs) are used together. Concomitant use may increase the risk of hyperkalemia.
Amlodipine; Olmesartan: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin II receptor antagonists are used together. Concomitant use may increase the risk of hyperkalemia.
Amlodipine; Valsartan: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin II receptor antagonists are used together. Concomitant use may increase the risk of hyperkalemia.
Amlodipine; Valsartan; Hydrochlorothiazide, HCTZ: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin II receptor antagonists are used together. Concomitant use may increase the risk of hyperkalemia.
Angiotensin II receptor antagonists: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin II receptor antagonists are used together. Concomitant use may increase the risk of hyperkalemia.
Angiotensin-converting enzyme inhibitors: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin-converting enzyme inhibitors (ACE inhibitors) are used together. Concomitant use may increase the risk of hyperkalemia.
Atropine; Difenoxin: (Moderate) Drugs that decrease GI motility, like diphenoxylate/difenoxin, may increase the risk of GI irritation from sustained-release solid oral dosage forms of potassium salts. Immediate release potassium formulations may be preferred in patients requiring diphenoxylate/difenoxin therapy.
Azilsartan: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin II receptor antagonists are used together. Concomitant use may increase the risk of hyperkalemia.
Azilsartan; Chlorthalidone: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin II receptor antagonists are used together. Concomitant use may increase the risk of hyperkalemia.
Benazepril: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin-converting enzyme inhibitors (ACE inhibitors) are used together. Concomitant use may increase the risk of hyperkalemia.
Benazepril; Hydrochlorothiazide, HCTZ: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin-converting enzyme inhibitors (ACE inhibitors) are used together. Concomitant use may increase the risk of hyperkalemia.
Bupivacaine; Meloxicam: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and nonsteroidal anti-inflammatory drugs (NSAIDs) are used together. Concomitant use may increase the risk of hyperkalemia.
Candesartan: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin II receptor antagonists are used together. Concomitant use may increase the risk of hyperkalemia.
Candesartan; Hydrochlorothiazide, HCTZ: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin II receptor antagonists are used together. Concomitant use may increase the risk of hyperkalemia.
Captopril: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin-converting enzyme inhibitors (ACE inhibitors) are used together. Concomitant use may increase the risk of hyperkalemia.
Captopril; Hydrochlorothiazide, HCTZ: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin-converting enzyme inhibitors (ACE inhibitors) are used together. Concomitant use may increase the risk of hyperkalemia.
Celecoxib: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and nonsteroidal anti-inflammatory drugs (NSAIDs) are used together. Concomitant use may increase the risk of hyperkalemia.
Celecoxib; Tramadol: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and nonsteroidal anti-inflammatory drugs (NSAIDs) are used together. Concomitant use may increase the risk of hyperkalemia.
Chlorpheniramine; Ibuprofen; Pseudoephedrine: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and nonsteroidal anti-inflammatory drugs (NSAIDs) are used together. Concomitant use may increase the risk of hyperkalemia.
Cyclosporine: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and cyclosporine are used together. Concomitant use may increase the risk of hyperkalemia.
Diclofenac: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and nonsteroidal anti-inflammatory drugs (NSAIDs) are used together. Concomitant use may increase the risk of hyperkalemia.
Diclofenac; Misoprostol: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and nonsteroidal anti-inflammatory drugs (NSAIDs) are used together. Concomitant use may increase the risk of hyperkalemia.
Diflunisal: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and nonsteroidal anti-inflammatory drugs (NSAIDs) are used together. Concomitant use may increase the risk of hyperkalemia.
Digoxin: (Minor) Potassium levels should be monitored closely in patients receiving digoxin and potassium supplementation. Both hypokalemia and hyperkalemia increase the risk of digoxin toxicity. Some patients at increased risk are patients with renal impairment, patients on diuretics, and patients who are on potassium-sparing medications concurrently. Monitor renal function, potassium concentrations, and digoxin concentrations and clinical response during concurrent treatment.
Diphenhydramine; Ibuprofen: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and nonsteroidal anti-inflammatory drugs (NSAIDs) are used together. Concomitant use may increase the risk of hyperkalemia.
Diphenhydramine; Naproxen: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and nonsteroidal anti-inflammatory drugs (NSAIDs) are used together. Concomitant use may increase the risk of hyperkalemia.
Diphenoxylate; Atropine: (Moderate) Drugs that decrease GI motility, like diphenoxylate/difenoxin, may increase the risk of GI irritation from sustained-release solid oral dosage forms of potassium salts. Immediate release potassium formulations may be preferred in patients requiring diphenoxylate/difenoxin therapy.
Drospirenone: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and drospirenone are used together. Concomitant use may increase the risk of hyperkalemia. Drospirenone has anti-mineralocorticoid activity, including the potential for hyperkalemia in high-risk patients, comparable to 25 mg of spironolactone.
Drospirenone; Estetrol: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and drospirenone are used together. Concomitant use may increase the risk of hyperkalemia. Drospirenone has anti-mineralocorticoid activity, including the potential for hyperkalemia in high-risk patients, comparable to 25 mg of spironolactone.
Drospirenone; Estradiol: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and drospirenone are used together. Concomitant use may increase the risk of hyperkalemia. Drospirenone has anti-mineralocorticoid activity, including the potential for hyperkalemia in high-risk patients, comparable to 25 mg of spironolactone.
Drospirenone; Ethinyl Estradiol: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and drospirenone are used together. Concomitant use may increase the risk of hyperkalemia. Drospirenone has anti-mineralocorticoid activity, including the potential for hyperkalemia in high-risk patients, comparable to 25 mg of spironolactone.
Drospirenone; Ethinyl Estradiol; Levomefolate: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and drospirenone are used together. Concomitant use may increase the risk of hyperkalemia. Drospirenone has anti-mineralocorticoid activity, including the potential for hyperkalemia in high-risk patients, comparable to 25 mg of spironolactone.
Enalapril, Enalaprilat: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin-converting enzyme inhibitors (ACE inhibitors) are used together. Concomitant use may increase the risk of hyperkalemia.
Enalapril; Hydrochlorothiazide, HCTZ: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin-converting enzyme inhibitors (ACE inhibitors) are used together. Concomitant use may increase the risk of hyperkalemia.
Eplerenone: (Contraindicated) The use of potassium supplements in patients receiving eplerenone for the treatment of hypertension is contraindicated. Concomitant use may increase the risk of hyperkalemia. Minimize the risk of hyperkalemia with proper patient selection and monitoring.
Eprosartan: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin II receptor antagonists are used together. Concomitant use may increase the risk of hyperkalemia.
Eprosartan; Hydrochlorothiazide, HCTZ: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin II receptor antagonists are used together. Concomitant use may increase the risk of hyperkalemia.
Etodolac: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and nonsteroidal anti-inflammatory drugs (NSAIDs) are used together. Concomitant use may increase the risk of hyperkalemia.
Fenoprofen: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and nonsteroidal anti-inflammatory drugs (NSAIDs) are used together. Concomitant use may increase the risk of hyperkalemia.
Finerenone: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and finerenone are used together. Concomitant use may increase the risk of hyperkalemia.
Flurbiprofen: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and nonsteroidal anti-inflammatory drugs (NSAIDs) are used together. Concomitant use may increase the risk of hyperkalemia.
Fosinopril: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin-converting enzyme inhibitors (ACE inhibitors) are used together. Concomitant use may increase the risk of hyperkalemia.
Fosinopril; Hydrochlorothiazide, HCTZ: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin-converting enzyme inhibitors (ACE inhibitors) are used together. Concomitant use may increase the risk of hyperkalemia.
Hydrochlorothiazide, HCTZ; Moexipril: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin-converting enzyme inhibitors (ACE inhibitors) are used together. Concomitant use may increase the risk of hyperkalemia.
Hydrocodone; Ibuprofen: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and nonsteroidal anti-inflammatory drugs (NSAIDs) are used together. Concomitant use may increase the risk of hyperkalemia.
Ibuprofen: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and nonsteroidal anti-inflammatory drugs (NSAIDs) are used together. Concomitant use may increase the risk of hyperkalemia.
Ibuprofen; Famotidine: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and nonsteroidal anti-inflammatory drugs (NSAIDs) are used together. Concomitant use may increase the risk of hyperkalemia.
Ibuprofen; Oxycodone: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and nonsteroidal anti-inflammatory drugs (NSAIDs) are used together. Concomitant use may increase the risk of hyperkalemia.
Ibuprofen; Pseudoephedrine: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and nonsteroidal anti-inflammatory drugs (NSAIDs) are used together. Concomitant use may increase the risk of hyperkalemia.
Indomethacin: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and nonsteroidal anti-inflammatory drugs (NSAIDs) are used together. Concomitant use may increase the risk of hyperkalemia.
Iodoquinol: (Moderate) Iodoquinol should be used with caution in patients treated with thyroid agents. Iodine-containing compounds like iodoquinol may result in overt thyroid disease.
Irbesartan: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin II receptor antagonists are used together. Concomitant use may increase the risk of hyperkalemia.
Irbesartan; Hydrochlorothiazide, HCTZ: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin II receptor antagonists are used together. Concomitant use may increase the risk of hyperkalemia.
Ketoprofen: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and nonsteroidal anti-inflammatory drugs (NSAIDs) are used together. Concomitant use may increase the risk of hyperkalemia.
Ketorolac: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and nonsteroidal anti-inflammatory drugs (NSAIDs) are used together. Concomitant use may increase the risk of hyperkalemia.
Lisinopril: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin-converting enzyme inhibitors (ACE inhibitors) are used together. Concomitant use may increase the risk of hyperkalemia.
Lisinopril; Hydrochlorothiazide, HCTZ: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin-converting enzyme inhibitors (ACE inhibitors) are used together. Concomitant use may increase the risk of hyperkalemia.
Lithium: (Moderate) Lithium can precipitate goiter and/or hypothyroidism. Concomitant use of lithium and potassium iodide, KI can increase the likelihood of this adverse reaction.
Losartan: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin II receptor antagonists are used together. Concomitant use may increase the risk of hyperkalemia.
Losartan; Hydrochlorothiazide, HCTZ: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin II receptor antagonists are used together. Concomitant use may increase the risk of hyperkalemia.
Meclofenamate Sodium: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and nonsteroidal anti-inflammatory drugs (NSAIDs) are used together. Concomitant use may increase the risk of hyperkalemia.
Mefenamic Acid: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and nonsteroidal anti-inflammatory drugs (NSAIDs) are used together. Concomitant use may increase the risk of hyperkalemia.
Meloxicam: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and nonsteroidal anti-inflammatory drugs (NSAIDs) are used together. Concomitant use may increase the risk of hyperkalemia.
Methimazole: (Moderate) Potassium iodide should not be used concurrently with other antithyroid agents. Agents such as methimazole and propylthiouracil, PTU can increase the likelihood of hypothyroidism when used in combination with potassium iodide.
Moexipril: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin-converting enzyme inhibitors (ACE inhibitors) are used together. Concomitant use may increase the risk of hyperkalemia.
Nabumetone: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and nonsteroidal anti-inflammatory drugs (NSAIDs) are used together. Concomitant use may increase the risk of hyperkalemia.
Naproxen: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and nonsteroidal anti-inflammatory drugs (NSAIDs) are used together. Concomitant use may increase the risk of hyperkalemia.
Naproxen; Esomeprazole: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and nonsteroidal anti-inflammatory drugs (NSAIDs) are used together. Concomitant use may increase the risk of hyperkalemia.
Naproxen; Pseudoephedrine: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and nonsteroidal anti-inflammatory drugs (NSAIDs) are used together. Concomitant use may increase the risk of hyperkalemia.
Nebivolol; Valsartan: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin II receptor antagonists are used together. Concomitant use may increase the risk of hyperkalemia.
Nonsteroidal antiinflammatory drugs: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and nonsteroidal anti-inflammatory drugs (NSAIDs) are used together. Concomitant use may increase the risk of hyperkalemia.
Olmesartan: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin II receptor antagonists are used together. Concomitant use may increase the risk of hyperkalemia.
Olmesartan; Amlodipine; Hydrochlorothiazide, HCTZ: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin II receptor antagonists are used together. Concomitant use may increase the risk of hyperkalemia.
Olmesartan; Hydrochlorothiazide, HCTZ: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin II receptor antagonists are used together. Concomitant use may increase the risk of hyperkalemia.
Oxaprozin: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and nonsteroidal anti-inflammatory drugs (NSAIDs) are used together. Concomitant use may increase the risk of hyperkalemia.
Penicillin G: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and high doses of penicillin G potassium are used together. Concomitant use may increase the risk for hyperkalemia. Penicillin G potassium contains 1.7 mEq of potassium per million units of penicillin G activity.
Perindopril: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin-converting enzyme inhibitors (ACE inhibitors) are used together. Concomitant use may increase the risk of hyperkalemia.
Perindopril; Amlodipine: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin-converting enzyme inhibitors (ACE inhibitors) are used together. Concomitant use may increase the risk of hyperkalemia.
Piroxicam: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and nonsteroidal anti-inflammatory drugs (NSAIDs) are used together. Concomitant use may increase the risk of hyperkalemia.
Propylthiouracil, PTU: (Contraindicated) Potassium iodide should not be used concurrently with other antithyroid agents. Agents such as methimazole and propylthiouracil, PTU can increase the likelihood of hypothyroidism when used in combination with potassium iodide.
Quinapril: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin-converting enzyme inhibitors (ACE inhibitors) are used together. Concomitant use may increase the risk of hyperkalemia.
Quinapril; Hydrochlorothiazide, HCTZ: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin-converting enzyme inhibitors (ACE inhibitors) are used together. Concomitant use may increase the risk of hyperkalemia.
Ramipril: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin-converting enzyme inhibitors (ACE inhibitors) are used together. Concomitant use may increase the risk of hyperkalemia.
Sacubitril; Valsartan: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin II receptor antagonists are used together. Concomitant use may increase the risk of hyperkalemia.
Sodium Iodide: (Contraindicated) The recent intake of antithyroid agents will affect the uptake of radioiodide from sodium iodide, I-131; patients must discontinue all medications and supplements that may interfere with iodide uptake into thyroid tissue prior to therapy with sodium iodide I-131. Various protocols are used. Many manufacturers state that concurrent antithyroid agents should be discontinued at least 3 to 4 days before administration of radioiodide. The following withdrawal timing recommendations were set forth in a procedure guideline published by the Society of Nuclear Medicine in February 2002. Antithyroid agents may affect iodide protein binding for an average of 5 days after administration; allow a 3 day wash out period for the antithyroid agent prior to sodium iodide I-131 administration. The antithyroid agent may be resumed 2 to 3 days after treatment.
Sodium Polystyrene Sulfonate: (Contraindicated) Sodium polystyrene sulfonate is indicated for the treatment of hyperkalemia. Administration of all potassium salts should be discontinued whenever therapy with sodium polystyrene sulfonate is indicated.
Sparsentan: (Moderate) Monitor potassium during concomitant use of sparsentan and potassium. Concomitant use increases the risk for hyperkalemia.
Spironolactone: (Major) The use of potassium supplements in patients receiving spironolactone may increase the risk for hyperkalemia. Potassium supplements should generally be avoided in heart failure patients receiving spironolactone. Monitor serum potassium concentrations closely if concomitant use is necessary.
Spironolactone; Hydrochlorothiazide, HCTZ: (Major) The use of potassium supplements in patients receiving spironolactone may increase the risk for hyperkalemia. Potassium supplements should generally be avoided in heart failure patients receiving spironolactone. Monitor serum potassium concentrations closely if concomitant use is necessary.
Sulfamethoxazole; Trimethoprim, SMX-TMP, Cotrimoxazole: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and trimethoprim are used together. Concomitant use may increase the risk of hyperkalemia.
Sulindac: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and nonsteroidal anti-inflammatory drugs (NSAIDs) are used together. Concomitant use may increase the risk of hyperkalemia.
Sumatriptan; Naproxen: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and nonsteroidal anti-inflammatory drugs (NSAIDs) are used together. Concomitant use may increase the risk of hyperkalemia.
Tacrolimus: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and tacrolimus are used together. Concomitant use may increase the risk of hyperkalemia.
Telmisartan: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin II receptor antagonists are used together. Concomitant use may increase the risk of hyperkalemia.
Telmisartan; Amlodipine: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin II receptor antagonists are used together. Concomitant use may increase the risk of hyperkalemia.
Telmisartan; Hydrochlorothiazide, HCTZ: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin II receptor antagonists are used together. Concomitant use may increase the risk of hyperkalemia.
Thyroid hormones: (Moderate) Antithyroid agents should generally not be administered with the thyroid hormones due to their opposing effects. However, in selected cases some clinicians coadminister T4 (e.g., levothyroxine) to circumvent drug-induced hypothyroidism when large suppressive doses of antithyroid agents are administered for long periods of time. However, clinical and biochemical euthyroid status may usually be maintained with careful titration of the antithyroid agent dosage alone.
Tolmetin: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and nonsteroidal anti-inflammatory drugs (NSAIDs) are used together. Concomitant use may increase the risk of hyperkalemia.
Trandolapril: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin-converting enzyme inhibitors (ACE inhibitors) are used together. Concomitant use may increase the risk of hyperkalemia.
Trandolapril; Verapamil: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin-converting enzyme inhibitors (ACE inhibitors) are used together. Concomitant use may increase the risk of hyperkalemia.
Triamterene: (Major) The use of potassium supplements in patients treated with triamterene is generally contraindicated. Concomitant use may increase the risk of hyperkalemia. If potassium supplementation is used, monitor serum potassium concentrations closely.
Triamterene; Hydrochlorothiazide, HCTZ: (Major) The use of potassium supplements in patients treated with triamterene is generally contraindicated. Concomitant use may increase the risk of hyperkalemia. If potassium supplementation is used, monitor serum potassium concentrations closely.
Trimethoprim: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and trimethoprim are used together. Concomitant use may increase the risk of hyperkalemia.
Valdecoxib: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and nonsteroidal anti-inflammatory drugs (NSAIDs) are used together. Concomitant use may increase the risk of hyperkalemia.
Valsartan: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin II receptor antagonists are used together. Concomitant use may increase the risk of hyperkalemia.
Valsartan; Hydrochlorothiazide, HCTZ: (Moderate) Monitor serum potassium concentrations closely if potassium supplements and angiotensin II receptor antagonists are used together. Concomitant use may increase the risk of hyperkalemia.

Potassium Iodide/SSKI Oral Sol: 1mL, 1g, 65mg

Dosage must be individualized to the indication for use, patient age, and clinical response.

Mechanism of Action: Potassium iodide (KI) supplies iodine systemically. The pharmacology of potassium iodide is not completely understood, despite years of use in clinical medicine for various medical conditions.
•Effects on the thyroid gland: Iodides are usually used in the treatment of hyperthyroidism to prepare patients for thyroidectomy. Iodides are also used along with antithyroid drugs and symptomatic treatments for the acute treatment of thyrotoxic crisis. By inhibiting thyroid hormone synthesis and release, thyroid gland vascularity is reduced, thyroid gland tissue becomes firmer, thyroid cell proliferation is reduced, follicular colloid reaccumulates, and bound iodine levels increase. The response of the hyperthyroid patient to iodide treatment is usually rapid, with symptomatic changes noted within 24 hours, although maximal effects may not be apparent until 2 weeks later. Although the effects may be noted for several weeks, iodides do not usually control the disease indefinitely, which is the reason why patients often need other measures (e.g., thyroidectomy) for treatment. The effects of iodides on the thyroid gland are complex, and can be dependent on the baseline thyroid status of the patient. Euthyroid patients or patients with certain underlying thyroid disorders may be at risk for iodine-induced hypothyroidism if they are exposed to large amounts of iodine systemically.
•Effects as a thyroid protectant prior to/following exposure to radioiodines: During a nuclear accident, various iodine isotopes are produced, including 131I, a radioactive iodine that concentrates in the thyroid gland. 131I has an 8-day half-life, which means that 99% of the radioactivity will decay in roughly 56 days. Potassium iodide (KI) is considered a safe and effective means by which to prevent radioiodine uptake by the thyroid gland and to minimize the risk of radiation-induced thyroid cancer. The administration of KI saturates the thyroid gland with iodine, minimizing the uptake of the radioactive isotope. For optimal protection against inhaled radioiodines following a radiation emergency, KI should be administered immediately coincident with the passage of the radioactive cloud, although KI may still have a substantial protective effect if taken 3 to 4 hours after the exposure.
•Effects in inflammatory dermatoses: The precise actions by which potassium iodide is therapeutically beneficial for various dermatologic conditions are not known. It appears that the drug may have some effects on inhibiting neutrophil chemotaxis, actions which might be beneficial in certain inflammatory dermatoses that display increased neutrophil activation in early stages of the disease. In dermatoses caused by yeast and fungi, potassium iodide appears to act as an antifungal, although it is not clear if the drug is directly fungicidal or works by enhancing the tissue and immune response to the infection.

Potassium iodide is administered orally. It demonstrates significant extracellular distribution, with most of the drug accumulating in the thyroid gland. Potassium iodide distributes into breast milk and crosses the placenta in amounts sufficient enough to cause fetal harm (see Contraindications). Therapeutic effects from KI usually are observed within 24 hours after administration, with maximum effectiveness occurring after 10—15 days of therapy. Potassium iodide is excreted renally.

Potassium iodide is absorbed from the GI tract as iodinated amino acids.

Potassium iodide, KI crosses the placenta in amounts sufficient enough to cause fetal harm, fetal goiter and abnormal thyroid function during human pregnancy. Because of the possible development of fetal goiter, if the drug is used during pregnancy or if a female of childbearing potential becomes pregnant during therapy, apprise the patient of the potential hazard. The use of iodides as expectorant agents during pregnancy is contraindicated, due to the non-essential indication for use in the mother compared to the fetal thyroid risk. Prolonged use for thyroid disease during pregnancy is not advised, however, potassium iodide has been used short term (e.g., 10 days) to manage labor-induced thyrotoxic crisis and as treatment prior to thyroidectomy in pregnant women. Pregnant women may also take potassium iodide if they are contaminated with radioactive iodine or if they receive inadvertent exposure to radioiodine (radioactive iodine, I-131) and are advised to do so by their healthcare professional or governmental agencies, according to current guidelines for radiation emergencies. Women should not self-supplement with potassium iodide during pregnancy.

Potassium iodide, KI is excreted into breast milk. Rash or thyroid suppression can possibly occur in the nursing infant. Potassium iodide therapy would only be used in a lactating woman when medically necessary for thyroid protection or hyperthyroid emergencies; use as an expectorant is not advised. Breast-feeding women should take potassium iodide if they are contaminated with radioactive iodine and advised to do so by their governmental agencies, according to current guidelines for radiation emergencies. The normal amount of potassium iodide present in human breast milk is not sufficient to protect an infant who has been exposed to radioactive Iodine-131. Thus, in an environmental exposure, the breast-feeding infant must receive supplemental potassium iodide to block uptake of radiation in the infant's thyroid gland.